Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Contact lens consolidation

This article was originally published in The Gray Sheet

  • News

Executive Summary

Essilor subsidiary BBGR has signed an agreement to make an outright purchase of all Rupp & Hubrach capital. Rupp & Hubrach, which is BBGR's German ocular products distributor, is Germany's fifth-ranked corrective lens manufacturer, generating approximately $54 mil. in revenue last year, according to BBGR. France-based Essilor is owned by Ocular Sciences (1"The Gray Sheet" Feb. 19, 2001, p. 16)...

Table

View full table

Tags:
Latest Headlines

New Guidance For Breast Cancer Screening Drops Age Of First Scan To 40

CDRH’s AR/VR Home Space Will Serve As An ‘Idea Lab’ For Device Stakeholders

Digital Health Roundup: US FDA’s ‘Idea Lab’; Philips’ Roy Jakobs On AI Draft Framework; Apple Watch

EU Regulatory Roundup, April 2024: EU On Cusp Of Regulatory Shifts Amidst Political Change

See All
UsernamePublicRestriction

Register

MT018033

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By